Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20163005 | 0.89 | MAPT (0.38) | MAPTKDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL20163006 | 0.89 | MAPT (0.38) | MAPTKDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL20173288 | 0.89 | MAPT (0.38) | MAPTKDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL20162858 | 0.73 | MAPT (0.44) | MAPTKDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL20173293 | 0.73 | MAPT (0.44) | MAPTKDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL20162856 | 0.73 | MAPT (0.44) | MAPTKDM4ESMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3788898 | 0.70 | SRC (0.61) | MAPTKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3788895 | 0.70 | SRC (0.61) | MAPTKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL13019972 | 0.70 | SRC (0.61) | MAPTKDM4ESMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3711762 | 0.67 | MAPT (0.51) | MAPTKDM4ESMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION | 2019-07-25 | — | — | US | disclosed |
| WO-2018094137-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225621-A1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CFTR, P2RX1, P2RX5 | MAPT 4878/4885KDM4E 4438/4885SMN1; SMN2 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.